- Fate Therapeutics (FATE +13%) opens at $6.56 and moves sharply higher.
- The offering priced at the low-end of its expected range, notable because the company had already lowered the range to $6-8 from $14-16.
- FATE's lead product is ProHema, a hematopoietic stem cell therapeutic derived from umbilical cord blood.
Fate Therapeutics jumps in debut
Oct 1 2013, 11:23 ET